ACURA PHARMACEUTICALS, INC: debt financing — Acura receives $200K in new loans from controlling shareholder; debt due May 31, warns of possible bankruptcy

ACURA PHARMACEUTICALS, INC

Secured note principal now $7,794,279 with ~$650,000 accrued interest; 5.25% interest rate, due May 31, 2025.
New $100,000 loans from controlling shareholder AD Pharma on April 4 and April 18, 2025; AD Pharma owns ~65% of Acura common stock.
If not paid by May 31, 2025, overdue amounts bear default interest at 7.5% per annum.
Without additional financing by mid-May 2025, Acura warns it may scale back operations, furlough employees, or seek bankruptcy; total loss of shareholder value possible.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ACURA PHARMACEUTICALS, INC incurred loan of loans of $100,000 with Abuse Deterrent Pharma, LLC at 5.25% maturing May 31, 2025.

Instrument: loan
Principal: loans of $100,000
Counterparty: Abuse Deterrent Pharma, LLC
Rate: 5.25%
Maturity: May 31, 2025
Event: incurrence

Exact text from the filing

On each of April 4, 2025 and April 18, 2025 we received loans of $100,000 from Abuse Deterrent Pharma, LLC ("AD Pharma").

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0001104659-25-037976

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.